Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open flat
Mon, 28 Sep 09:30 am

The major Asian stock marketsAsian stock markets have opened the day in red. Stock markets in Indonesia, Japan and Singapore are trading lower by 1.7%, 1.4% and 0.6% respectively. The major stock indices in the European markets ended their previous session on an encouraging note. However, the benchmark indices in US ended their previous session down by 1%. The rupee is trading at 66.04 per US dollar.

Back home, the Indian stock markets have opened the day on a flattish note. BSE-Sensex is trading up by 27 points (up 0.1%) while, NSE-Nifty is trading down by 1 points (down 0.01%). Both S&P BSE Midcap and S&P BSE Smallcap have opened on an encouraging note and are trading up by 0.4% and 0.5% respectively. Sectoral indices have opened the day on a mixed note with stocks from banking and information technology (IT) sector witnessing the maximum buying interest. However stocks from metals & mining and automobile sector are witnessing selling pressure.

As per an article in Business Standard, Maruti Suzuki raised the average gross salary of its workers in its Manesar and Gurgoan plants. The salary has been hiked by Rs 16800 per month. However this wage hike is spread over the three years. Reportedly, the estimated financial impact of the wage hike on the company during the current financial year is estimated at Rs 1.30 bn. Further, this cost is expected to be Rs 0.65 bn for the second and third year each. However the company has already budgeted for the increase. The stock of Maruti Suzuki is trading down by 0.2%.

As per an article in Economic Times, U.S Food and Drug Administration (USFDA) has cancelled an approval issued to Sun Pharma Advance Research Company (SPARC) in relation to launch of a drug for seizures. SPARC is the research arm of Sun Pharmaceutical Ltd. The approval has been revoked citing manufacturing quality problems at its production site. The move comes as a setback to SPARC as the drug 'Elepsia XR' was its first one to receive an FDA approval. Reportedly, it was estimated the sales of this drug could be around USD$ 50 m annually from Elepsia XR. The stock of SPARC and Sun Pharmaceutical is trading down by 3% & 2.4% respectively.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open flat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.